Amgen UK’s Chris Fox: Up for the Challenge
Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of…
Address: 4th Floor 44-46 Whitfield Street London W1T 2RJ,United Kingdom
Tel: +44 (0) 20 7388 7722
Web: http://www.arktherapeutics.com/main/index.php?content=home_page
Ark Therapeutics Group plc is an innovative gene-based medicine company with operations in the UK and Finland. Ark seeks to capitalize on its pipeline of programs in high value areas of unmet medical need within vascular disease and cancer Ark has also developed a small molecule platform based on its acknowledged leadership in vascular biology and is currently working on an exciting NRP-1 antagonist program which is already the subject of interest from major pharmaceutical companies.
Ark is distinguished by:
• Development products addressing clear, unmet needs
• Highly valuable GMP manufacturing expertise, characterized by a proven expertise in chemistry and manufacturing control and development of biological in approved facilities.
• Broad follow-on preclinical portfolio – Ark’s founding scientists have acknowledged world-renowned expertise in vascular biology and molecular medicine.
Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of…
A spinout from the Roslin Institute that created Dolly the Sheep, Roslin CT is a cell and gene therapy CDMO, with a unique positioning in the field today. Its CEO,…
Jonny Ohlson, founder & CEO of Touchlight, discusses the genetic medicine revolution and the role of Touchlight in disrupting the field with its revolutionary DNA technology. You founded Touchlight Genetics…
Dr. Geoffrey Guy, chairman and founder of cannabinoid medicine pioneer, GW Pharma, outlines the potential benefits that Brexit could bring to the UK’s life sciences industry and the evolution of…
KaNDy Therapeutics, a UK-based biotech has raised £25 million to finance the Phase 2b trial of their breakthrough product in Women’s Health. Our investors and the KaNDy management team are united…
Sterling Pharma Solutions is a rapidly growing GMP contract API manufacturer based out of Dudley, Cramlington in the Northeast of England. The company was set up in its current structure…
Offering genomic sequencing and analysis, Congenica operates in the exciting world of genomic diagnosis, with a particular focus on rare diseases. Its CEO David Atkins describes the potential of Congenica’s…
Sean Richardson discusses Alexion’s focus on rare and ultra-rare diseases, the level of support for these therapies from the UK government, awareness raising, diagnostics, and his future priorities. …
With over 30 years of experience in the life sciences industry, Angela McFarlane explains why the UK will not be removed from its position in the top 3 for new…
For Ipsen, the UK is one of three global hubs, with manufacturing in Wales in which it is continuously investing, as well as large-scale R&D activities near Oxford. Ipsen’s general…
Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms…
Professor David Garway-Heath, a specialist in glaucoma, talks with us about the screening devices of the future, low awareness of glaucoma as a chronic disease and collaboration in training and…
See our Cookie Privacy Policy Here
